PARK CITY, Utah--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced they will be hosting two virtual R&D Investor calls for analysts and investors focused on the Company’s etrasimod programs. The Company will also participate in five upcoming investor conferences throughout September.
Virtual Investor Call Webcast Information
In addition to presentations by Arena’s senior management team, the investor calls will feature presentations by and Q&A with renowned key opinion leaders.
Gastroenterology Investor Call
- Robert Lisicki, Executive Vice President and Chief Commercial Officer, Arena Pharmaceuticals
- William Sandborn, MD, Distinguished Professor of Medicine; University of California San Diego
The video webcast will be broadcast live in listen-only mode from 10:30 a.m. ET to 11:30 a.m. ET on Tuesday, September 21, 2021. Register for the event here. An archived webcast of the call will be available on the investor relations section of Arena's website at www.arenapharm.com.
Dermatology Investor Call
- Doug Manion, MD, Executive Vice President, Head of Research and Development, Arena Pharmaceuticals
- Jonathan Silverberg, MD, PhD, MPH, Associate Professor, Director of Clinical Research; George Washington University School of Medicine and Health Sciences
The video webcast will be broadcast live in listen-only mode from 11:00 a.m. ET to 12:00 p.m. ET on Monday, September 27, 2021. Register for the event here. An archived webcast of the call will be available on the investor relations section of Arena's website at www.arenapharm.com.
September Investor Conferences
Arena management will provide an overview of the Company during investor meetings and presentations at five upcoming investor conferences:
- Citi 2021 BioPharma Virtual Conference – September 9th
- Wells Fargo Virtual Healthcare Conference – September 10th
- H.C. Wainwright 23rd Annual Global Investment Conference – September 13th & 14th
- Morgan Stanley Global Healthcare Conference – September 15th
- Cantor Fitzgerald Virtual Global Healthcare Conference – September 28th & 29th
Etrasimod (APD334) is a next generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena and designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5, which may lead to an improved efficacy and safety profile. Etrasimod is intended to provide systemic and local effects on specific immune cell types and has the potential to treat multiple immune-mediated inflammatory diseases including ulcerative colitis, Crohn’s disease, eosinophilic esophagitis, atopic dermatitis, and alopecia areata.
Etrasimod is an investigational compound that is not approved for any use in any country.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients.
In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done.
We are developing a richly diversified portfolio of therapeutic candidates targeting gastroenterology, dermatology and cardiology. To fuel our growth, we are unlocking the value of our historical GPCR research with a sustainable discovery engine for broad portfolio expansion.
ARENA - Care More. Act Differently.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements may be identified by words such as “designed for,” “may,” “lead to,” “intended,” and “potential to,” and include, without limitation, statements about the potential benefits of etrasimod, and Arena’s purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: topline data may not accurately reflect the complete results of a particular study or trial; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; the timing and outcome of research, development and regulatory review is uncertain, and Arena’s drug candidates may not advance in development or be approved for marketing; enrolling patients in Arena’s ongoing and intended clinical trials is competitive and challenging; the duration and severity of the coronavirus disease (COVID-19) pandemic, including but not limited to the impact on Arena’s clinical operations, the operations of Arena’s suppliers, partners, collaborators, licensees, and capital markets, which in each case remains uncertain; risks related to developing and commercializing drugs; Arena will need additional funds to advance all of its programs; the impact of competition; risks related to unexpected or unfavorable new data; the risk that regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; satisfactory resolution of litigation or other disagreements with others; and risks related to the enforcement of Arena’s and third parties’ intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Arena’s forward-looking statements are disclosed in Arena’s filings with the Securities and Exchange Commission (SEC), including but not limited to Arena’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, which was filed with the SEC on August 5, 2021. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.